Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes.
Altoe ML, Kalinsky K, Marone A, Kim HK, Guo H, Hibshoosh H, Tejada M, Crew KD, Accordino MK, Trivedi MS, Hershman DL, Hielscher AH. Altoe ML, et al. Among authors: guo h. Clin Cancer Res. 2021 Apr 1;27(7):1949-1957. doi: 10.1158/1078-0432.CCR-20-1108. Epub 2021 Jan 15. Clin Cancer Res. 2021. PMID: 33451976 Free PMC article.
Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
Vanguri RS, Fenn KM, Kearney MR, Wang Q, Guo H, Marks DK, Chin C, Alcus CF, Thompson JB, Leu CS, Hibshoosh H, Kalinsky KM, Mathews JC, Nadeem S, Hollmann TJ, Connolly EP. Vanguri RS, et al. Among authors: guo h. Clin Breast Cancer. 2022 Aug;22(6):538-546. doi: 10.1016/j.clbc.2022.04.002. Epub 2022 Apr 18. Clin Breast Cancer. 2022. PMID: 35610143 Free PMC article.
Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer.
Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart T, Lu Y, Pan Q, Yu J, Hibshoosh H, Guo H, Andreopoulou E, Wiechmann L, Crew K, Sparano J, Hershman D, Connolly E, Saenger Y, Kalinsky K. Marks DK, et al. Among authors: guo h. Front Oncol. 2020 Jun 16;10:968. doi: 10.3389/fonc.2020.00968. eCollection 2020. Front Oncol. 2020. PMID: 32612958 Free PMC article.
Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin.
Marks DK, Kucharczyk J, Kim P, Chyong DI, Gartrell RD, Lu Y, Hibshoosh H, Guo H, Evans TRJ, Lopez J, Kristeleit R, Connolly E, Saenger Y, Kalinsky K. Marks DK, et al. Among authors: guo h. Cancer Invest. 2021 Jul-Aug;39(6-7):466-472. doi: 10.1080/07357907.2021.1938109. Epub 2021 Jun 21. Cancer Invest. 2021. PMID: 34075851
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
Sahoo S, Krings G, Chen YY, Carter JM, Chen B, Guo H, Hibshoosh H, Reisenbichler E, Fan F, Wei S, Khazai L, Balassanian R, Klein ME, Shad S, Venters SJ, Borowsky AD, Symmans WF, Ocal IT. Sahoo S, et al. Among authors: guo h. Arch Pathol Lab Med. 2022 May 1;147(5):591-603. doi: 10.5858/arpa.2022-0021-EP. Arch Pathol Lab Med. 2022. PMID: 35976643 Free article.
21,270 results
You have reached the last available page of results. Please see the User Guide for more information.